Patterns of Lymph Node Metastases in Apparent Stage I Low-Grade Epithelial Ovarian Cancer: A Multicenter Study

Minig, Lucas; Heitz, Florian; Cibula, David; Bakkum-Gamez, Jamie N.; Germanová, Anna; Dowdy, Sean C.; Kalogera, Eleftheria; Zapardiel, Ignacio; Lindemann, Kristina; Harter, Philipp; Scambia, Giovanni; Petrillo, Marco; Zorrero, Cristina; Zanagnolo, Vanna; Rebollo, José Miguel Cárdenas; Bois, Andreas du; Fotopoulou, Christina

doi:10.1245/s10434-017-5919-y

Cited by 43 publications

(35 citation statements)

References 18 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…13 The limitations of this study included no data being available regarding peritoneal involvement of disease and there is a possibility that patients undergoing IDS have a higher burden LGSOC, 10.7% of women had positive lymph nodes (LN). 34 Interestingly the upstaging of patients due to LN involvement alone occurred in only 2.4% of women and there was no significant difference in OS or PFS between LN positive and negative patients. 34 Of note, fewer patients in the LN negative group received chemotherapy.…”

Section: Gradingmentioning

confidence: 86%

“…Interestingly the upstaging of patients due to LN involvement alone occurred in only 2.4% of women and there was no significant difference in OS or PFS between LN positive and negative patients . Of note, fewer patients in the LN negative group received chemotherapy …”

Section: Clinical Course and Treatmentmentioning

confidence: 95%

“…Potential confounders included disease biology, upstaging and selection bias and further research is needed. Concerning apparent stage I disease, a retrospective study ( n = 163) on low‐grade EOC (LGSOC n = 56) found among LGSOC, 10.7% of women had positive lymph nodes (LN) . Interestingly the upstaging of patients due to LN involvement alone occurred in only 2.4% of women and there was no significant difference in OS or PFS between LN positive and negative patients .…”

Section: Clinical Course and Treatmentmentioning

confidence: 99%

“…Concerning apparent stage I disease, a retrospective study ( n = 163) on low‐grade EOC (LGSOC n = 56) found among LGSOC, 10.7% of women had positive lymph nodes (LN) . Interestingly the upstaging of patients due to LN involvement alone occurred in only 2.4% of women and there was no significant difference in OS or PFS between LN positive and negative patients . Of note, fewer patients in the LN negative group received chemotherapy …”

Section: Clinical Course and Treatmentmentioning

confidence: 99%

“…Careful patient selection is crucial and includes women of childbearing age (≤40 years), those having received adequate counselling regarding oncological and fertility outcomes, patient compliance to follow up, correct disease staging including unilateral salpingo‐ophorectomy, peritoneal washings, excision of any suspicious peritoneal lesions, multiple peritoneal biopsies, an omentectomy and traditionally pelvic and para‐aortic lymphadenectomy followed by histological review by a dedicated gynaecological pathologist . However, as noted, the role of lymphadenectomy in early stage disease is not fully established and may not confer a PFS or OS benefit . For women inadvertently diagnosed with an early cancer, referral to a gynaecological oncologist is essential.…”

Section: Early Stage Disease and Fertility Preservationmentioning

confidence: 99%

See 4 more Smart Citations

Low‐grade serous ovarian carcinoma: A comprehensive literature review

Goulding

Simcock

McLachlan

et al. 2019

Aust NZ J Obst Gynaeco

View full text Add to dashboard Cite

Background Low‐grade serous ovarian carcinoma (LGSOC) is a unique entity with clinical and molecular characteristics distinct from high‐grade serous ovarian carcinoma (HGSOC). To date the majority of research has focused on the more common HGSOC, with treatment recommendations often extrapolated to LGSOC. Women with LGSOC are typically diagnosed younger and have indolent and relatively chemoresistant disease. Recently there have been major research advances in LGSOC. Aims This systematic review describes the epidemiological, clinical and molecular characteristics of LGSOC, with advances in research and novel treatment options also discussed. Materials and Methods A 10‐year comprehensive systematic review of peer‐reviewed literature was conducted, with a total of 132 abstracts read, 89 articles reviewed and 49 included in this review. Results This review highlights the clinical and molecular features of LGSOC, current and traditional treatment options and areas of current research into targeted agents. Conclusions Our growing knowledge about LGSOC as a distinct clinical and molecular entity from HGSOC has led to the investigation of more targeted and tailored therapies as their clinical course, optimal management and therapeutic targets differ. There is a need for ongoing collaborative research to provide better treatment options for these patients.

show abstract

Section: Gradingmentioning

confidence: 86%

Section: Clinical Course and Treatmentmentioning

confidence: 95%

Section: Clinical Course and Treatmentmentioning

confidence: 99%

Section: Clinical Course and Treatmentmentioning

confidence: 99%

Section: Early Stage Disease and Fertility Preservationmentioning

confidence: 99%

See 3 more Smart Citations

Low‐grade serous ovarian carcinoma: A comprehensive literature review

Goulding

Simcock

McLachlan

et al. 2019

Aust NZ J Obst Gynaeco

View full text Add to dashboard Cite

show abstract

How to manage lymph nodes in ovarian cancer

Harter

Heitz

Ataseven

et al. 2019

Cancer

Self Cite

View full text Add to dashboard Cite

The indication for staging lymphadenectomy in patients with ovarian cancer (both early-and late-stage disease) has been a major topic of debate in the last decades. Because the Lymphadenectomy in Ovarian Neoplasms (LION) study has recently demonstrated that systematic lymphadenectomy is not beneficial to patients with advanced ovarian cancer, the discussion has become more complex for patients with early-stage ovarian cancer. Further factors, such as differences in the lymph node metastasis rates of different histologic subtypes, which were not known in the past, need to be taken into account. This review is focused on the available evidence concerning lymphadenectomy in patients with newly diagnosed ovarian cancer. Cancer 2019;125:4573-4577.

show abstract

Impact of cytoreductive surgery on survival of patients with low‐grade serous ovarian carcinoma: A multicentric study of Turkish Society of Gynecologic Oncology (TRSGO‐OvCa‐001)

Vatansever

Taşkiran

Meydanlı

et al. 2021

Journal of Surgical Oncology

View full text Add to dashboard Cite

Background and Objectives: The aim of this study was to analyze the factors affecting recurrence-free (RFS) and overall survival (OS) rates of women diagnosed with low-grade serous ovarian cancer (LGSOC).Methods: Databases from 13 participating centers in Turkey were searched retrospectively for women who had been treated for stage I-IV LGSOC between 1997 and 2018.Results: Overall 191 eligible women were included. The median age at diagnosis was 49 years (range, 21-84 years). One hundred seventy-five (92%) patients underwent primary cytoreductive surgery. Complete and optimal cytoreduction was achieved in 148 (77.5%) and 33 (17.3%) patients, respectively. The median follow-up period was 44 months

show abstract

Patterns of Lymph Node Metastases in Apparent Stage I Low-Grade Epithelial Ovarian Cancer: A Multicenter Study

Cited by 43 publications

References 18 publications

Low‐grade serous ovarian carcinoma: A comprehensive literature review

Low‐grade serous ovarian carcinoma: A comprehensive literature review

How to manage lymph nodes in ovarian cancer

Impact of cytoreductive surgery on survival of patients with low‐grade serous ovarian carcinoma: A multicentric study of Turkish Society of Gynecologic Oncology (TRSGO‐OvCa‐001)

Contact Info

Product

Resources

About